How Does Medical Device Reimbursement Work? The Coding, Coverage, Payment Framework

2026-07-03 · Caduvo Team

A plain-language explainer of the coding-coverage-payment framework for US medical device reimbursement. Covers CPT/HCPCS codes, Medicare vs. commercial payers, and why reimbursement strategy must begin before design freeze.

Reimbursement is the reason a better device doesn’t always win. It’s why some founders get to Series B and others don’t. It’s also a system that obeys clear, learnable rules.

The coding–coverage–payment framework is the backbone of US medical device reimbursement. Get one piece wrong, and you don’t get paid, no matter how innovative your device.

Here’s how the pieces fit together, why Medicare’s decisions echo through commercial payers, and what to do before design freeze.

The Three-Legged Stool: Coding, Coverage, Payment

Every medical device reimbursement path runs through three sequential gates.

Coding. A code tells the payer what you did and what you used. Without a code, the claim can’t be submitted.

• CPT Category I codes (e.g., 33249 for pacemaker insertion) describe established procedures and devices. The AMA CPT Editorial Panel updates these codes. Getting a new one takes 12–24 months.
• HCPCS Level II codes (e.g., C1823 for a generator, implantable neurostimulator) cover devices, supplies, and drugs not in CPT. CMS issues these.
• Category III codes are temporary CPT codes for emerging technologies. They track utilization but rarely guarantee payment.

Coverage. A coverage decision says whether the payer will reimburse for a code in a given clinical scenario. Medicare makes coverage calls nationally (National Coverage Determinations, NCDs) or locally (Local Coverage Determinations, LCDs, via Medicare Administrative Contractors). Commercial payers often follow Medicare’s lead but may add their own medical-necessity criteria.

Payment. Payment sets the dollar amount. Under Medicare’s OPPS or MPFS, that’s often based on the Ambulatory Payment Classification (APC) or the Relative Value Unit (RVU) assigned to the code.

A device can have a code, no coverage, and zero payment. Or coverage with a payment rate below the cost of the device. The sequence matters.

Medicare Medical Device Reimbursement vs. Commercial Payers

Medicare covers roughly 60 million people and is the pacesetter. Its coverage and payment decisions influence UnitedHealthcare, Aetna, and the Blues. But the mechanics differ.

Medicare medical device reimbursement pathways:

• Inpatient (Part A). The device is bundled into a Medicare Severity-Diagnosis Related Group (MS-DRG) payment to the hospital. If no DRG fits, a new-technology add-on payment (NTAP) can temporarily bridge the gap.
• Outpatient (Part B). Device is often packaged into an APC payment or paid separately via pass-through status (temporary) or a unique HCPCS code.
• Physician office (Part B). If the clinician buys the device and bills for it, you need a code with a practice-expense RVU that covers the device cost.

Commercial payers write their own medical policies. They frequently require published clinical data and may mirror an NCD or LCD. The gap between an FDA clearance and a positive medical policy is what kills early-stage companies. A 510(k) doesn’t mean a payer will write a check.

Why Reimbursement Strategy Starts Before Design Freeze

The FDA pathway dictates the evidence package. The evidence package underpins the coding and coverage case. Changing the device design after that is expensive.

A coherent medical device reimbursement strategy answers four questions early:

1. What codes could this device map to today?
2. Is there an existing coverage policy that includes or excludes this device category?
3. What endpoints will payers demand before they cover this?
4. What’s the gap between the likely payment rate and the intended ASP?

If the answer to #4 is negative, you have a price-to-payment mismatch that no amount of sales effort will fix. Catch it during concept, not pre-launch.

A Real-World Sequence

A startup building a disposable arthroscopic device intended for use in ASCs learns this the hard way. The procedure already has a CPT code, but the device is packaged into the APC payment. The surgeon’s reimbursement doesn’t increase if they use your $800 device instead of the $200 standard version.

Options at prototype stage: redesign for a procedure that’s paid separately, gather cost-effectiveness data for a new HCPCS code request, or target a different site of service. Options six months before launch: slim.

Four-Action Checklist for Early-Stage Device Companies

1. Map the current coding footprint. Search the CMS HCPCS file and your top five surgeon’s current claims for CPT codes. Identify whether your device falls into an existing code or requires a new one.
2. Pull LCDs and payer medical policies. Read the LCDs for your MAC region and the policies of three large commercial plans. Note every requirement: specific diagnosis, prior authorization, trial of conservative therapy.
3. Model payment. For physician-office/outpatient, build a mock Medicare claim to see the professional fee, technical fee, and device pass-through eligibility. For inpatient, confirm the MS-DRG and the cost threshold that would justify an NTAP application.
4. Set evidence milestones. List the studies you need, their endpoints, and the date by which a coverage dossier must be submitted. Work backward from a realistic coverage effective date, not an FDA clearance date.

How to Spot Reimbursement Risk in 15 Minutes

This is a triage, not a full strategy. Run it before your next board update.

• If no CPT or HCPCS code describes the device, assume an 18-month minimum to get one.
• If a code exists but no MAC has published a related LCD, coverage is inconsistent — you’ll need to educate payers one by one.
• If the ASP exceeds the device-offset portion of the bundled payment by more than 30%, expect slow uptake.

These aren’t reasons to stop. They are reasons to adjust the clinical trial design, label indications, or pricing model now.

Taking the Next Step

A medical device reimbursement strategy that waits for design freeze is a fundraising and adoption risk. You can pull CMS data, payer policies, and code pathways manually, but staying current across 50 states and multiple payers is why tools like Caduvo exist — to surface coding gaps, coverage restrictions, and payment rates in one search instead of weeks of legwork. Whether you use a platform or a spreadsheet, the rule is the same: start the reimbursement work before the IFU is final.